The Combination Effects of Vorinostat and Silver Nanoparticles Targeting Angiogenesis, Oxidative Stress, and Inflammation: An In Vitro Study
نویسندگان
1 Department of Medical Laboratory Sciences, Faculty of Science, Al-Balqa Applied University, Al-Salt 19117, Jordan
2 Department of Nutrition and Food Technlolgy. University of Jordan, Amman 11942, Jordan
3 Department of Medical Laboratory Sciences, Faculty of Science, Al-Balqa Applied University, Al-Salt 19117, Jordan
4 Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman 19328, Jordan
5 Department of Cosmetic Science, Pharmacological and Diagnostic Research Centre, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman 19328, Jordan
6 Department of Pharmaceutical Sciences, Al-Ahliyya Amman University, Amman 19328, Jordan
7 Department of Medical Laboratory Sciences, Faculty of Science, Mutah University, Al-Karak 61710, Jordan
doi
10.26655/JMCHEMSCI.2024.10.15چکیده
Vorinostat, a histone deacetylase inhibitor (HDACi), has shown promising anticancer effects, but its use is limited by its cytotoxicity and growing resistance. Therefore, this study aims to evaluate the combined effect of vorinostat and silver nanoparticles (SNPs) on cancer cell lines by assessing their cytotoxicity, anti-angiogenic, anti-inflammatory, and antioxidant activities to improve the effectiveness and lessen the adverse effects of vorinostat. The combination of vorinostat and SNPs was tested on different cancer cell lines, along with normal fibroblasts. The anti-proliferative effect was assessed using different concentration of vorinostat and SNPs and the expression levels of vascular endothelial factor (VEGF), matrix metalloproteinase 9 (MMP9), Tumor necrosis factor alpha (TNFα), interleukin I beta (IL-1β), glutathione peroxidase (GPX), and catalase (CAT) markers were evaluated by ELISA. The combined treatment of vorinostat and SNPs significantly increased the anti-proliferative in cancer cells compared to monotherapies. A significant reduction in VEGF, MMP9, TNFα, and IL-1β levels as well as decreased GPX and CAT levels was observed. In conclusion the results suggest that both vorinostat and SNPs have anticancer activity. Furthermore, it was indicated that this combination modifies the inflammation, oxidation and angiogenetic process in cancer cells, which may improve their therapeutic potential suggesting that this combination therapy offers a promising approach for overcoming the limitations of vorinostat monotherapy, including drug resistance and off-target toxicity.
